PRECISION, BURITY AND PERFORMANCE

Let's talk about precision in medical aesthetics. Whether you're an experienced practitioner or new to the field, you know how critical precision is for delivering patient satisfaction.

Discover Nuceiva (botulinum toxin type A)-a neuromodulator that's designed for precision.

Nuceiva is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.1

As readers will know, Nuceiva should only be administered by healthcare practitioners with appropriate qualifications and expertise in the treatment of glabellar lines and the use of required equipment.

Designed for Precision: It starts with the patented Hi-Pure technology. This unique manufacturing process yields a product that is 2:95% pure.2 ' That's not just a claim; it's backed by a rigorous manufacturing method.

• The Hi-Pure technology reduces impurities: By utilising a series of anion exchange chromatography columns that absorb process-related and product-related impurities, while allowing the drug substance to flow through for collection, impurities are reduced2

• The process defines the product: The process combines Hi-Pure TM technology with vacuum drying to optimise the final product quality and produce a precise product2

• Nuceiva® is a unique neuromodulator:1 As with every botulinum neuromodulator, Nuceiva is unique and not interchangeable.

What's in the vial? Each vial of Nuceiva® contains 50 units of botulinum toxin type A, derived from C/ostridium botulinum, along with human albumin and sodium chloride. No preservatives, no unnecessary additives - just a simple, precise formula. Just store the unopened vials at 2-8° C to maintain effectiveness (shelf-life 30 months).1

It's all about your precise technique. Neuromodulators require precise intramuscular injection techniques to target the correct glabellar muscles and deliver the desired clinical results.1 Check in with your Evolus team for details of our latest training events.

This is where your skills meet the science to achieve patient satisfaction. In a study, just over 94% of Nuceiva patients expressed a positive response (improved or much improved) at 30 days after treatment.3 And let's not overlook safety. According to the label, Nuceiva® generally has a 1% rate of eyelid ptosis.1

As a practitioner, you have options. So why choose Nuceiva®? The answer lies in its combination of precision and patient satisfaction.

At Evolus, we are all about evolving the future of Performance Beauty. If you are a healthcare professional,join our community to learn more.

Adverse events should be reported. Reporting forms and information can be found atwww.mhra.gov.uk/yellowcard or search MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Evolus International Ltd at medical information@evolus.com or 08000541302.